Prostatic Artery Embolization Research Articles

Abstract No. 142 Impact of Virtual Injection Software on Radiation Exposure and Operative Time during Prostate Artery Embolization

To investigate the influence of a cone-beam CT (CBCT) based Virtual Injection software on patient radiation exposure during prostate artery embolization (PAE). All consecutive patients from January 2019 to May 2022 treated with PAE using CBCT at a single institution were retrospectively analyzed. Radiation exposure (Total Air Kerma (AK), Peak Skin Dose (PSD)), fluoroscopy time (FT) and operation time were recorded. The influence of age, body mass index (BMI), radial access and use of Virtual Injection software (Embo ASSIST, GE Healthcare, Chicago, IL) were assessed. A total of 131 patients had PAE with CBCT, of whom 77 patients (77/131;58.8%) using Virtual Injection software and 40 (40/131;30.5%) using radial access. Radial access and Virtual Injection both significantly reduced AK, PSD and FT with respectively (601 ± 503 vs. 962 ± 593 mGy, P = 0.01) and (642 ± 451 vs. 1150 ± 637 mGy, P = 0.01); (295 ± 243 vs. 683 ± 476 mGy, P< 0.001) and (358 ± 251 vs. 860 ± 510 mGy, P = 0.001); (33 ± 15.3 vs. 43,1 ± 18.6 min, P = 0.004) and (35.6 ± 15.4 vs. 46.6 ± 20 min, P = 0.001). Virtual Injection use also significantly reduced operation time (94.6 ± 41.3 min vs. 115.2 ± 39.6, P = 0.005). In multivariate analysis, AK and PSD reduction were associated with lower patient BMI, shorter FT and Virtual Injection use. FT and operation time reduction were associated with Virtual Injection use. The use of Virtual Injection software in PAE planning and guidance is associated with reduced radiation exposure and operative time.

Abstract No. 602 Real World Radiation Exposure During Prostate Artery Embolization with Mobile Angiography: A Review of Over 700 Procedures

Abstract No. 602 Real World Radiation Exposure During Prostate Artery Embolization with Mobile Angiography: A Review of Over 700 Procedures

Abstract No. 604 Modern Search Analytics: What Are Patients Asking about Prostate Artery Embolization?

Abstract No. 604 Modern Search Analytics: What Are Patients Asking about Prostate Artery Embolization?

Abstract No. 513 What’s Trending? Analysis of TikTok Results for Prostate, Uterine, and Genicular Artery Embolization

Abstract No. 513 What’s Trending? Analysis of TikTok Results for Prostate, Uterine, and Genicular Artery Embolization

Abstract No. 288 Prostate Artery Embolization in Prostate Glands Greater than 80 g: A Single Center Experience

Abstract No. 288 Prostate Artery Embolization in Prostate Glands Greater than 80 g: A Single Center Experience

Abstract No. 144 Cone-Beam CT with Dedicated Planning Software Improves Optimal Gantry Angle Selection for Prostate Artery Embolization

Abstract No. 144 Cone-Beam CT with Dedicated Planning Software Improves Optimal Gantry Angle Selection for Prostate Artery Embolization

Abstract No. 599 Comparison of Safety and Feasibility of Prostate Artery Embolization via Transradial Access versus Transfemoral Access: A Single-Center Experience

Abstract No. 599 Comparison of Safety and Feasibility of Prostate Artery Embolization via Transradial Access versus Transfemoral Access: A Single-Center Experience

Abstract No. 286 Prostate Artery Embolization and Minimally Invasive Urologic Procedures for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis

Abstract No. 286 Prostate Artery Embolization and Minimally Invasive Urologic Procedures for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis

Abstract No. 149 Impact of Cone-Beam CT and Augmented Planning on Complete Prostatic Vascular Anatomy Identification for Prostatic Artery Embolization

Abstract No. 149 Impact of Cone-Beam CT and Augmented Planning on Complete Prostatic Vascular Anatomy Identification for Prostatic Artery Embolization

Abstract No. 509 Safety and Efficacy of Prostate Artery Embolization Utilizing n-BCA Glue

Abstract No. 509 Safety and Efficacy of Prostate Artery Embolization Utilizing n-BCA Glue

Abstract No. 3 ▪ ABSTRACT OF THE YEAR Prostate Artery Embolization—Single-Center Experience of 1,000 Patients with Short-, Mid- and Long-Term Follow-Up

Abstract No. 3 ▪ ABSTRACT OF THE YEAR Prostate Artery Embolization—Single-Center Experience of 1,000 Patients with Short-, Mid- and Long-Term Follow-Up

Abstract No. 283 Impact of Repeat Prostate Artery Embolization on Sexual Function

Abstract No. 283 Impact of Repeat Prostate Artery Embolization on Sexual Function

Abstract No. 281 Impact of Pre-Procedural Medications on Prostate Artery Embolization Outcomes

Abstract No. 281 Impact of Pre-Procedural Medications on Prostate Artery Embolization Outcomes

Long-term outcomes of prostate artery embolization for acute urinary retention: An analysis of 88 patients

PurposeThe purpose of this study was to assess long-term outcome of prostate artery embolization (PAE) in patients presenting with acute urinary retention related to benign prostatic hyperplasia. Materials and methodsAll consecutive patients who underwent PAE for acute urinary retention due to benign prostatic hyperplasia from August 2011 to December 2021 in a single institution were retrospectively included. There were 88 men with a mean age of 72 ± 12 (standard deviation [SD]) years (range: 42–99 years). Patients underwent a first attempt of catheter removal two weeks after PAE. Clinical success was defined as the absence of acute urinary retention recurrence. Correlations between long-term clinical success and patient variables or bilateral PAE were searched for using Spearman correlation test. Catheter-free survival was assessed using Kaplan-Meier analysis. ResultsSuccessful catheter removal in the month following PAE was performed in 72 (72/88; 82%) patients and 16 (16/88; 18%) patients had immediate recurrence. Clinical success persisted for 58 (58/88; 66%) patients at long-term follow-up (mean follow-up: 19.5 months ± 16.5 [SD]; range: 2–74 months). Recurrence occurred at a mean of 16.2 months ± 12.2 (SD) (range: 1.5–43 months) post-PAE. Overall, 21 (21/88; 24%) patients of the cohort underwent prostatic surgery, at a mean of 10.4 months ± 12.2 (SD) (range: 1.2–42.4 months) from initial PAE. No correlations between patients variables or bilateral PAE and long-term clinical success were identified. Kaplan-Meier analysis showed a three-year catheter free probability of 60%. ConclusionPAE is a valuable technique for acute urinary retention related to benign prostatic hyperplasia, with a long-term success rate of 66%. However acute urinary retention relapse affects 15% of patients.

Does prostate artery embolization prior to Aquablation® reduce peri-operative morbidity and increase the likelihood of same day discharge?

Does prostate artery embolization prior to Aquablation® reduce peri-operative morbidity and increase the likelihood of same day discharge?

Non-inferiority, randomized, open-label clinical trial on the efficacy of transurethral microwave thermotherapy compared to prostatic artery embolisation in reducing severe lower urinary tract symptoms in men with benign prostatic hyperplasia

Non-inferiority, randomized, open-label clinical trial on the efficacy of transurethral microwave thermotherapy compared to prostatic artery embolisation in reducing severe lower urinary tract symptoms in men with benign prostatic hyperplasia

Contrast-enhanced magnetic resonance angiography in the identification of prostatic arterial anatomy in patients with benign prostatic hyperplasia: prospective comparison with digital subtraction angiography

To evaluate the utility of contrast-enhanced magnetic resonance angiography (CE-MRA) for identifying prostatic artery (PA) anatomy in patients with benign prostatic hyperplasia (BPH) before PA embolisation (PAE), using digital subtraction angiography (DSA) as the reference standard. A total of 176 patients underwent pelvic CE-MRA at 3 T. DSA was performed within the following 7 days. Two interventional radiologists compared the CE-MRA findings with DSA findings to assess the anatomy of the PAs. The rates of correct identification of the origins and collaterals of the PAs by CE-MRA were calculated. The utility for predicting the optimal X-ray tube angle obliquity for visualising the origins of the PAs by CE-MRA was evaluated. An exact McNemar's test was used to compare the detection rates of the PAs and the collaterals with DSA versus CE-MRA. A two-sided p-value of <0.05 was considered statistically significant. Of the 376 PAs identified by DSA, CE-MRA correctly identified the origins of 369 vessels (98.1%), with a 1.9% false-negative rate and no false-positive results. Of the 57 total collaterals identified by DSA, CE-MRA identified 50 vessels correctly (87.7%), with a 12.3% false-negative rate and no false-positive results. No significant differences were observed between CE-MRA and DSA in the identification of the PA origins (p=0.824) and the collaterals (p=0.327). The optimal degree for an oblique projection to visualise the origins of the PAs could be predicted accurately (100%) by pre-procedural CE-MRA. CE-MRA before PAE can reliably predict the PA anatomy and facilitate procedural planning.

Transperineal laser ablation as a new minimally invasive surgical therapy for benign prostatic hyperplasia: a systematic review of existing literature.

Transperineal laser ablation (TPLA) of the prostate is a new, minimally invasive technique for benign prostatic hyperplasia (BPH) with promising effectiveness and safety outcomes. This systematic review aims to provide an update of existing literature. A literature review was performed in Pubmed/MEDLINE, Embase, Cochrane Library, and clinicaltrials.gov from January 2000 up to April 2023. Data extraction and risk of bias were performed independently by three authors. A total of 11 studies were included, among which 9 were observational, 1 randomized controlled trial, 1 animal study, while 2 of them were comparative (1 with prostatic artery embolization and 1 with transurethral resection of the prostate). Functional outcomes were improved in the majority of studies both for objective (maximum flow rate and post-void residual) and subjective outcomes (improvement of International Prostate Symptom Score and quality of life). Complication rates ranged between 1.9% and 2.3% for hematuria, 3.7% and 36.3% for dysuria, 1.9% and 19% for acute urinary retention, 0.6% and 9.1% for orchitis/urinary tract infections, and 0.6% and 4.8% for prostatic abscess formation. Regarding sexual function, >95% of patients retained their ejaculation while erectile function was maintained or improved. TPLA of the prostate is an innovative, minimally invasive technique for managing patients with BPH. Existing studies indicate an effective technique in reducing International Prostate Symptom Score and quality of life scores, post-void residual reduction, and increase in Qmax, albeit the measured improvements in terms of Qmax are not equal to transurethral resection of the prostate. Although sexual function is maintained, the mean catheterization time is 7 days, and no long-term data are available for most patients.

Treatment of Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the widespread diseases affecting aging males globally. As prostatic cell proliferation, it clinically influences a great degree of bladder outlet obstruction and is characterized by bothersome lower urinary tract symptoms. Assessments and treatments should not only be conducted based on the prostate volume or condition, related symptoms and quality of life should be considered also. The present analysis focuses on the update of management for BPH, including pharmacotherapy and slightly invasive surgical options. Despite alpha-1 adrenoceptor antagonists, many other factors and even combination therapy were extensively studied. Regarding slightly invasive surgical treatments, including Aquablation, water vapor thermal therapy, prostatic artery embolization, prostatic urethral lift, and nitinol butterfly-like stent, we analyzed the latest findings of studies, as well as safety issues. Finally, we highlighted current guidelines for clinical practice and future direction for further investigation.

Prostatic Artery Embolization: An Update.

Prostatic Artery Embolization: An Update.